

Ablation Technology Market Assessment, By Product [Radiofrequency Ablators, Ultrasound Ablators, Laser/Light Ablators, Electrical Ablators, Cryoablation Devices, Microwave Ablators, Hydrothermal/Hydromechanical Ablators, Consumables], By Application [Cardiovascular Disease Treatment, Cancer Treatment, Ophthalmological Treatment, Pain Management, Urological Treatment, Orthopedic Treatment, Cosmetic/Aesthetic Surgery, Others], By End-user [Hospitals, Surgical Centers, and Ablation Centers, Ambulatory Surgery Centers, Aesthetics and Dermatology Clinics, Others], By Region, Opportunities and Forecast, 2018-2032F

Market Report | 2025-04-22 | 227 pages | Market Xcel - Markets and Data

AVAILABLE LICENSES:

- Single User License \$4500.00
- Muti-User/Corporate Licence \$5700.00
- Custom Research License \$8200.00

Report description:

Global ablation technology market is projected to witness a CAGR of 8.70% during the forecast period 2025-2032, growing from USD 7.88 billion in 2024 to USD 15.37 billion in 2032 owing to the increasing demand for minimally invasive procedures, rising regulatory approvals for advanced devices, and a surge in strategic partnerships between medical device companies and healthcare providers. Additionally, the growing prevalence of chronic diseases like cancer and cardiovascular conditions contributes to market growth.

For instance, in March 2025, Abbott received CE mark approval in Europe for the Volt PFA System, developed to treat atrial fibrillation. This milestone highlights Abbott's progress in advancing electrophysiology and supports its plans to broaden Volt's availability across European countries later in the year.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Rising Regulatory Approvals for Ablation Technologies

The global ablation technology market is experiencing a surge in growth due to the rising number of regulatory approvals for innovative and advanced ablation devices. Health authorities like the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly granting approvals for novel devices aimed at treating a variety of diseases, including cancer, cardiovascular conditions, and neurological disorders. These regulatory advancements not only enhance the credibility of these products but also pave the way for their widespread adoption in healthcare settings worldwide. As new technologies are introduced and validated, healthcare providers are more inclined to adopt cutting-edge solutions that offer higher efficiency, improved patient outcomes, and enhanced safety. This increased approval activity for new technologies and devices, such as advanced cryoablation systems or radiofrequency ablation tools, fosters innovation and ensures that healthcare professionals have access to the best possible treatments. Moreover, the growth of minimally invasive techniques and the preference for non-surgical interventions further accelerates market expansion, particularly in the treatment of chronic diseases and tumors. For instance, in January 2025, Johnson & Johnson (U.S.) secured CE mark certification for its THERMOCOOL SMARTTOUCH SF catheter, intended for the treatment of cardiac arrhythmias, enabling further adoption across European markets.

Rise in Strategic Partnerships and Collaborations

The rise in strategic partnerships and collaborations is a key driver fueling growth in the global ablation technology market. As healthcare providers and manufacturers collaborate, there is a mutual exchange of resources, expertise, and technology that accelerates the development and commercialization of advanced ablation devices. These partnerships often include collaborations between medical device companies, academic institutions, and healthcare providers, leading to faster innovation and enhanced product offerings. For example, alliances with research institutions can lead to breakthroughs in ablation technologies, such as improved imaging systems or more effective energy delivery methods. Additionally, joint ventures with healthcare providers ensure that new devices and techniques are rapidly integrated into clinical practice. The benefits of these collaborations include expanded research and development capabilities, enhanced distribution networks, and access to new patient populations. The result is an accelerated market penetration of new ablation technologies, along with the assurance of effective and reliable treatments for patients. This collaborative approach is expected to continue driving market dynamics, with more partnerships emerging as the demand for innovative and effective therapies grows.

For instance, in February 2025, Japan Lifeline Co., Ltd. announced a strategic partnership with CardioFocus, Inc., focused on Pulsed Field Ablation (PFA) technology. Japan Lifeline has obtained licensing rights to CardioFocus's PFA System as part of this alliance, including PFA catheters and a generator. The two companies will work together on developing, producing, and distributing these systems, aiming to build a foundation for global commercialization in the future.

Expansion of Tumour Ablation Applications

The increasing prevalence of cancer has led to a significant expansion in the applications of tumor ablation technologies, particularly in minimally invasive treatments for liver, lung, kidney, and bone tumors. This shift is driven by the advantages of ablation procedures, such as reduced recovery times and lower complication rates compared to traditional surgeries. For instance, in March 2024, Medtronic plc received FDA 510(k) clearance for its OsteoCool 2.0 system, an advanced radiofrequency ablation device designed for the treatment of painful bone metastases and benign bone tumors. This approval underscores the growing adoption of ablation technologies in oncology, reflecting their efficacy and expanding role in cancer care.

North America Leading the Ablation Technology Market

North America is anticipated to maintain its leadership in the global ablation technology market, owing to its advanced healthcare infrastructure, high levels of healthcare spending, and widespread adoption of minimally invasive procedures. The increasing prevalence of chronic diseases such as cardiovascular conditions, cancer, and neurological disorders, which require ablation treatments, further strengthens the region's dominance. Additionally, favorable reimbursement policies and the strong presence of major market players, including Medtronic and Boston Scientific, contribute significantly to the region's growth. The rapid integration of advanced technologies, such as robotic-assisted and cryoablation devices, further enhances treatment outcomes, making North America a key market for innovative ablation solutions. With continuous advancements in research, the region is expected to maintain a competitive edge and drive substantial market growth in the coming years. Furthermore, strategic collaborations and partnerships between healthcare providers and leading device manufacturers further solidify North America's position as a global leader in ablation technology.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Future Market Scenario (2025-2032F)

The global ablation technology market is poised for substantial growth as technological advancements, increasing regulatory approvals, and expanding healthcare infrastructure drive adoption across diverse therapeutic applications. The demand for minimally invasive procedures, coupled with rising cases of chronic diseases and cancers, will continue to propel market expansion. Additionally, integrating artificial intelligence and robotics into ablation systems is expected to enhance precision and patient outcomes, further fueling market development. The market will also witness increased penetration in emerging economies. For instance, in September 2024, Boston Scientific Corporation (U.S.) received regulatory clearance from Japan's PMDA for its FARAPULSE Pulsed Field Ablation System, enabling the use of the device in pulmonary vein isolation procedures for paroxysmal atrial fibrillation.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of ablation technology and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

In November 2023, Johnson & Johnson MedTech (US) completed the acquisition of Laminar, Inc. (US), integrating the company into its Biosense Webster division to enhance its cardiac arrhythmia treatment portfolio and better address unmet clinical needs.

Table of Contents:

1. Project Scope and Definitions
2. Research Methodology
3. Executive Summary
4. Global Ablation Technology Market Outlook, 2018-2032F
- 4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
- 4.2. Market Share Analysis & Forecast
- 4.2.1. By Product
- 4.2.1.1. Radiofrequency Ablators
- 4.2.1.1.1. Temperature-Controlled Radiofrequency Ablators
- 4.2.1.1.2. Fluid-Cooled Radiofrequency Ablators
- 4.2.1.1.3. Robotic Catheter Manipulation Systems
- 4.2.1.2. Ultrasound Ablators
- 4.2.1.2.1. Ultrasonic Surgical Ablation Systems
- 4.2.1.2.2. High-Intensity Focused Ultrasound Ablators
- 4.2.1.2.3. Extracorporeal Shockwave Lithotripsy Systems
- 4.2.1.2.4. Magnetic Resonance-Guided Focused Ultrasound Ablators
- 4.2.1.3. Laser/Light Ablators
- 4.2.1.3.1. Excimer Laser Ablators
- 4.2.1.3.2. Cold Laser Ablators
- 4.2.1.4. Electrical Ablators
- 4.2.1.4.1. Argon Plasma/Beam Coagulators
- 4.2.1.4.2. Irreversible Electroporation Ablators
- 4.2.1.5. Cryoablation Devices
- 4.2.1.5.1. Tissue Contact Probes
- 4.2.1.5.2. Tissue Spray Probe
- 4.2.1.5.3. Epidermal and Subcutaneous Cryoablation Devices
- 4.2.1.6. Microwave Ablators
- 4.2.1.7. Hydrothermal/Hydromechanical Ablators

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2.1.8.□Consumables
- 4.2.2.□By Application
 - 4.2.2.1.□Cardiovascular Disease Treatment
 - 4.2.2.2.□Cancer Treatment
 - 4.2.2.2.1.□Liver Cancer
 - 4.2.2.2.2.□Kidney Cancer
 - 4.2.2.2.3.□Prostate Cancer
 - 4.2.2.2.4.□Lung Cancer
 - 4.2.2.2.5.□Others
 - 4.2.2.3.□Ophthalmological Treatment
 - 4.2.2.4.□Pain Management
 - 4.2.2.5.□Urological Treatment
 - 4.2.2.6.□Orthopedic Treatment
 - 4.2.2.7.□Cosmetic/Aesthetic Surgery
 - 4.2.2.8.□Others
- 4.2.3.□By End-user
 - 4.2.3.1.□Hospitals, Surgical Centers, and Ablation Centers
 - 4.2.3.2.□Ambulatory Surgery Centers
 - 4.2.3.3.□Aesthetics and Dermatology Clinics
 - 4.2.3.4.□Others
- 4.2.4.□By Region
 - 4.2.4.1.□North America
 - 4.2.4.2.□Europe
 - 4.2.4.3.□Asia-Pacific
 - 4.2.4.4.□South America
 - 4.2.4.5.□Middle East and Africa
- 4.2.5.□By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
- 4.3.□Market Map Analysis, 2024
 - 4.3.1.□By Product
 - 4.3.2.□By Application
 - 4.3.3.□By End-user
 - 4.3.4.□By Region
- 5.□North America Ablation Technology Market Outlook, 2018-2032F
 - 5.1.□Market Size Analysis & Forecast
 - 5.1.1.□By Value
 - 5.2.□Market Share Analysis & Forecast
 - 5.2.1.□By Product
 - 5.2.1.1.□Radiofrequency Ablators
 - 5.2.1.1.1.□Temperature-Controlled Radiofrequency Ablators
 - 5.2.1.1.2.□Fluid-Cooled Radiofrequency Ablators
 - 5.2.1.1.3.□Robotic Catheter Manipulation Systems
 - 5.2.1.2.□Ultrasound Ablators
 - 5.2.1.2.1.□Ultrasonic Surgical Ablation Systems
 - 5.2.1.2.2.□High-Intensity Focused Ultrasound Ablators
 - 5.2.1.2.3.□Extracorporeal Shockwave Lithotripsy Systems
 - 5.2.1.2.4.□Magnetic Resonance-Guided Focused Ultrasound Ablators
 - 5.2.1.3.□Laser/Light Ablators

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.1.3.1.□Excimer Laser Ablators
- 5.2.1.3.2.□Cold Laser Ablators
- 5.2.1.4.□Electrical Ablators
- 5.2.1.4.1.□Argon Plasma/Beam Coagulators
- 5.2.1.4.2.□Irreversible Electroporation Ablators
- 5.2.1.5.□Cryoablation Devices
- 5.2.1.5.1.□Tissue Contact Probes
- 5.2.1.5.2.□Tissue Spray Probe
- 5.2.1.5.3.□Epidermal and Subcutaneous Cryoablation Devices
- 5.2.1.6.□Microwave Ablators
- 5.2.1.7.□Hydrothermal/Hydromechanical Ablators
- 5.2.1.8.□Consumables
- 5.2.2.□By Application
- 5.2.2.1.□Cardiovascular Disease Treatment
- 5.2.2.2.□Cancer Treatment
- 5.2.2.2.1.□Liver Cancer
- 5.2.2.2.2.□Kidney Cancer
- 5.2.2.2.3.□Prostate Cancer
- 5.2.2.2.4.□Lung Cancer
- 5.2.2.2.5.□Others
- 5.2.2.3.□Ophthalmological Treatment
- 5.2.2.4.□Pain Management
- 5.2.2.5.□Urological Treatment
- 5.2.2.6.□Orthopedic Treatment
- 5.2.2.7.□Cosmetic/Aesthetic Surgery
- 5.2.2.8.□Others
- 5.2.3.□By End-user
- 5.2.3.1.□Hospitals, Surgical Centers, and Ablation Centers
- 5.2.3.2.□Ambulatory Surgery Centers
- 5.2.3.3.□Aesthetics and Dermatology Clinics
- 5.2.3.4.□Others
- 5.2.4.□By Country Share
- 5.2.4.1.□United States
- 5.2.4.2.□Canada
- 5.2.4.3.□Mexico
- 5.3.□Country Market Assessment
- 5.3.1.□United States Ablation Technology Market Outlook, 2018-2032F*
- 5.3.1.1.□Market Size Analysis & Forecast
- 5.3.1.1.1.□By Value
- 5.3.1.2.□Market Share Analysis & Forecast
- 5.3.1.2.1.□By Product
- 5.3.1.2.1.1.□Radiofrequency Ablators
- 5.3.1.2.1.1.1.□Temperature-Controlled Radiofrequency Ablators
- 5.3.1.2.1.1.2.□Fluid-Cooled Radiofrequency Ablators
- 5.3.1.2.1.1.3.□Robotic Catheter Manipulation Systems
- 5.3.1.2.1.2.□Ultrasound Ablators
- 5.3.1.2.1.2.1.□Ultrasonic Surgical Ablation Systems

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.3.1.2.1.2.2.□High-Intensity Focused Ultrasound Ablators
 - 5.3.1.2.1.2.3.□Extracorporeal Shockwave Lithotripsy Systems
 - 5.3.1.2.1.2.4.□Magnetic Resonance-Guided Focused Ultrasound Ablators
 - 5.3.1.2.1.3.□Laser/Light Ablators
 - 5.3.1.2.1.3.1.□Excimer Laser Ablators
 - 5.3.1.2.1.3.2.□Cold Laser Ablators
 - 5.3.1.2.1.4.□Electrical Ablators
 - 5.3.1.2.1.4.1.□Argon Plasma/Beam Coagulators
 - 5.3.1.2.1.4.2.□Irreversible Electroporation Ablators
 - 5.3.1.2.1.5.□Cryoablation Devices
 - 5.3.1.2.1.5.1.□Tissue Contact Probes
 - 5.3.1.2.1.5.2.□Tissue Spray Probe
 - 5.3.1.2.1.5.3.□Epidermal and Subcutaneous Cryoablation Devices
 - 5.3.1.2.1.6.□Microwave Ablators
 - 5.3.1.2.1.7.□Hydrothermal/Hydromechanical Ablators
 - 5.3.1.2.1.8.□Consumables
 - 5.3.1.2.2.□By Application
 - 5.3.1.2.2.1.□Cardiovascular Disease Treatment
 - 5.3.1.2.2.2.□Cancer Treatment
 - 5.3.1.2.2.2.1.□Liver Cancer
 - 5.3.1.2.2.2.2.□Kidney Cancer
 - 5.3.1.2.2.2.3.□Prostate Cancer
 - 5.3.1.2.2.2.4.□Lung Cancer
 - 5.3.1.2.2.2.5.□Others
 - 5.3.1.2.2.3.□Ophthalmological Treatment
 - 5.3.1.2.2.4.□Pain Management
 - 5.3.1.2.2.5.□Urological Treatment
 - 5.3.1.2.2.6.□Orthopedic Treatment
 - 5.3.1.2.2.7.□Cosmetic/Aesthetic Surgery
 - 5.3.1.2.2.8.□Others
 - 5.3.1.2.3.□By End-user
 - 5.3.1.2.3.1.□Hospitals, Surgical Centers, and Ablation Centers
 - 5.3.1.2.3.2.□Ambulatory Surgery Centers
 - 5.3.1.2.3.3.□Aesthetics and Dermatology Clinics
 - 5.3.1.2.3.4.□Others
 - 5.3.2.□Canada
 - 5.3.3.□Mexico
- *All segments will be provided for all regions and countries covered
- 6.□Europe Ablation Technology Market Outlook, 2018-2032F
 - 6.1.□Germany
 - 6.2.□France
 - 6.3.□Italy
 - 6.4.□United Kingdom
 - 6.5.□Russia
 - 6.6.□Netherlands
 - 6.7.□Spain
 - 6.8.□Turkey

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.9. Poland
- 7. Asia-Pacific Ablation Technology Market Outlook, 2018-2032F
 - 7.1. India
 - 7.2. China
 - 7.3. Japan
 - 7.4. Australia
 - 7.5. Vietnam
 - 7.6. South Korea
 - 7.7. Indonesia
 - 7.8. Philippines
- 8. South America Ablation Technology Market Outlook, 2018-2032F
 - 8.1. Brazil
 - 8.2. Argentina
- 9. Middle East and Africa Ablation Technology Market Outlook, 2018-2032F
 - 9.1. Saudi Arabia
 - 9.2. UAE
 - 9.3. South Africa
- 10. Demand Supply Analysis
- 11. Import and Export Analysis
- 12. Value Chain Analysis
- 13. Porter's Five Forces Analysis
- 14. PESTLE Analysis
- 15. Pricing Analysis
- 16. Market Dynamics
 - 16.1. Market Drivers
 - 16.2. Market Challenges
- 17. Market Trends and Developments
- 18. Regulatory Landscape and Innovation
- 19. Case Studies
- 20. Patient Epidemiology Data for Key Disease Indications
- 21. Competitive Landscape
 - 21.1. Competition Matrix of Top 5 Market Leaders
 - 21.2. SWOT Analysis for Top 5 Players
 - 21.3. Key Players Landscape for Top 10 Market Players
 - 21.3.1. Johnson & Johnson Services, Inc.
 - 21.3.1.1. Company Details
 - 21.3.1.2. Key Management Personnel
 - 21.3.1.3. Products and Services
 - 21.3.1.4. Financials (As Reported)
 - 21.3.1.5. Key Market Focus and Geographical Presence
 - 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
 - 21.3.2. Medtronic plc
 - 21.3.3. Boston Scientific Corporation
 - 21.3.4. AngioDynamics, Inc.
 - 21.3.5. Olympus Corporation
 - 21.3.6. AtriCure, Inc.
 - 21.3.7. Smith and Nephew plc

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

21.3.8. Accuray Incorporated

21.3.9. Conmed Corporation

21.3.10. Varian Medical Systems, Inc.

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Ablation Technology Market Assessment, By Product [Radiofrequency Ablators, Ultrasound Ablators, Laser/Light Ablators, Electrical Ablators, Cryoablation Devices, Microwave Ablators, Hydrothermal/Hydromechanical Ablators, Consumables], By Application [Cardiovascular Disease Treatment, Cancer Treatment, Ophthalmological Treatment, Pain Management, Urological Treatment, Orthopedic Treatment, Cosmetic/Aesthetic Surgery, Others], By End-user [Hospitals, Surgical Centers, and Ablation Centers, Ambulatory Surgery Centers, Aesthetics and Dermatology Clinics, Others], By Region, Opportunities and Forecast, 2018-2032F

Market Report | 2025-04-22 | 227 pages | Market Xcel - Markets and Data

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Muti-User/Corporate Licence	\$5700.00
	Custom Research License	\$8200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-08"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com